Intec Pharma Ltd. , a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has entered into agreements with several investors for the private placement of 2,289,638 ordinary shares of the Company, at a price of The ordinary shares to be issued by Intec in the private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in , absent registration under the Securities Act and applicable state securities laws or an applicable exemption from those registration requirements.
Category: Corporate / Securities Law
Fibrocell Announces Convertible Preferred Stock Financing for $8.0 Million
Fibrocell Science, Inc. , a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that it has entered into a securities purchase agreement with certain of its existing investors for the sale of $8.0 million of the Company’s Series A Convertible Preferred Stock and accompanying common stock warrants . Fibrocell has agreed to sell an aggregate of 8,000 units for a purchase price of $1,000 per Unit, with each Unit consisting of one share of Preferred Stock with an initial stated value of $1,000 convertible into shares of the Company’s common stock at a conversion price of $0.7757, and Warrants to purchase 10,313,263 shares of Common Stock .
Press release distribution, EDGAR filing, XBRL, regulatory filings
The links … )–Blackstone announced today that it has filed with the U.S. Securities and Exchange Commission its Annual Report on Form 10-K for the year ended December 31, 201… )–HFF has closed the $227 million sale of and arranged $175 million in financing for Tysons Metro Center, a four-building, Class A office portfolio totaling 763,965 squar… )–Rayonier Inc. announced today that the company’s board of directors has declared a first quarter cash dividend of $0.25 per common share. The dividen… )–John Gerspach, Chief Financial Officer of Citigroup, will present at the RBC Capital Markets 2017 Financial Institutions Conference on Tuesday, March 7, 2017.
Medovex Corp. Completes Financing
On February 9, 2017, Medovex Corporation entered into a unit purchase agreement with selected accredited investors. Pursuant to the terms of the agreement, the Company sold an aggregate of 2,905,770 shares and 1,452,885 warrants for gross proceeds of $3,022,000.
NEWS DuPont, Chemours to pay $670 million to settle PFOA claims
… Exchange Commission that it reached a “settlement in principle” with plaintiffs to resolve 3,550 lawsuits that allege health problems ranging from cancer to high cholesterol and thyroid problems. The settlement comes on the heels of a decision last …
Aevi Genomic Medicine Announces Enrollment of First Patient in Phase…
“We are pleased to have the first patient enrolled into this important study,” said Garry Neil, Chief Scientific Officer of Aevi Genomic Medicine. “Patients with 22q Deletion Syndrome often suffer from a range of debilitating psychiatric conditions, including anxiety disorders, ASD, and ADHD, with many patients progressing to psychosis and schizophrenia.
Cerecor Announces At-the-Market Equity Offering Program
… relapse and cocaine addiction. One trial is being conducted under the auspices of the National Institute of Mental Health, the second trial is a collaboration between Cerecor and Yale University with funding from the National Institutes of Health …
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Aetna Inc.
… treatment from regulators regarding the Humana acquisition; (2) Aetna threatened to limit its participation in public health insurance exchanges if the Department of Justice (“DOJ”) attempted to block the merger; (3) Aetna did not withdraw from …
Virtus Investment Advisers Inc. Acquires New Position in Humana Inc.
… company’s stock. The company has a consensus rating of “Buy” and an average price target of $213.00. Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail …
Progressive Care Engages PCAOB Auditing Firm to Begin Audit of 2016 Financial Statements
, through its subsidiary Pharmco LLC, a South Florida health services organization and provider of prescription pharmaceuticals specializing in health practice risk management, compounded medications, the sale of anti-retroviral medications and …
Leap Therapeutics and Macrocure Complete Merger Transaction
Leap Therapeutics, Inc. , a biotechnology company developing targeted and immuno-oncology therapeutics, today announced the completion of its merger with Macrocure Ltd , with Macrocure becoming a wholly-owned subsidiary of Leap. Leap will be listed on The Nasdaq Global Market under the symbol “LPTX” and expects to begin trading on Tuesday, January 24, 2017.
Check Cap LTD (Chek) Coverage Initiated by Analysts at Rodman & Renshaw
The brokerage issued a buy rating and a $6.00 price target on the stock. Separately, Maxim Group set a $6.00 target price on shares of CHECK CAP LTD and gave the company a buy rating in a report on Monday, October 24th.
EXACT Sciences Release: Company Grants Inducement Restricted Stock…
… and services; the acceptance of our products and services by patients and healthcare providers; the willingness of health insurance companies and other payors to cover CologuardA and reimburse us for our performance of the Cologuard test; the amount …
Proto Script Pharmaceutical Corp. Highlights Strong Revenue Growth in …
This Contract authorizes PSP Homecare to provide durable medical equipment , including high-quality mobility equipment to customers completely through Medicare insurance within numerous Competitive Bid Areas across California and Nevada. The Contract was issued under the Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies Competitive Bidding Program.
Press release distribution, EDGAR filing, XBRL, regulatory filings
… 5 – 8, 20… )–The U.S. Centers for Disease Control and Prevention (CDC) has selected ICF and its award-winning health communications practice for nine contracts with a combined val… )–Research and Markets has announced the addition of the “Fuel …
Exelixis Inc. (EXEL) Stake Raised by Swiss National Bank
Swiss National Bank increased its position in shares of Exelixis Inc. by 1.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission . The fund owned 367,300 shares of the biotechnology company’s stock after buying an additional 5,600 shares during the period.